Gasparyan Armen Yuri
Clinical Research Unit, Russell's Hall Hospital, Dudley Group of Hospitals NHS Foundation Trust, West Midlands, UK.
Vasc Health Risk Manag. 2010 Mar 24;6:109-12. doi: 10.2147/vhrm.s9087.
Antiplatelet drug resistance is one of the urgent issues in current cardiovascular medicine. Many platelet function tests have been used to define responsiveness of patients with cardiovascular disease to aspirin and clopidogrel. In most studies, cut-off values of platelet function tests for defining responsiveness to antiplatelets were chosen arbitrarily. Different tests provided wide-ranging figures of the prevalence of aspirin and clopidogrel resistance, suggesting poor correlation between currently available platelet function tests. Measurement of platelet size seems to be a promising approach for monitoring antiplatelet drug therapy. This commentary highlights some limitations of studies on aspirin and clopidogrel resistance in patients undergoing coronary interventions.
抗血小板药物抵抗是当前心血管医学中亟待解决的问题之一。许多血小板功能测试已被用于确定心血管疾病患者对阿司匹林和氯吡格雷的反应性。在大多数研究中，用于定义对抗血小板药物反应性的血小板功能测试的临界值是任意选择的。不同的测试给出了阿司匹林和氯吡格雷抵抗发生率的广泛数据，这表明目前可用的血小板功能测试之间相关性较差。血小板大小的测量似乎是监测抗血小板药物治疗的一种有前景的方法。本述评强调了在接受冠状动脉介入治疗的患者中关于阿司匹林和氯吡格雷抵抗研究的一些局限性。
